Pre- and post-chemotherapy alkaline phosphatase levels as prognostic indicators in adults with localised osteosarcoma

被引:53
作者
Bramer, JAM
Abudu, AA
Tillman, RM
Carter, SR
Sumathi, VP
Grimer, RJ
机构
[1] Royal Orthopaed Hosp, Birmingham B31 2AP, W Midlands, England
[2] Acad Med Ctr, Dept Orthopaed Surg, NL-1100 DD Amsterdam, Netherlands
关键词
osteosarcoma; adult; prognosis; alkaline phosphatase; subtype; response to chemotherapy; survival; local recurrence;
D O I
10.1016/j.ejca.2005.07.024
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The prognostic value of alkaline phosphatase (AP) measured before and after chemotherapy, but before surgery was established in a retrospective survey of patients. The patients were 18 years or older, with non-metastatic high-grade osteosarcoma. Pre-chemotherapy AP was available in 89 cases, post-chemotherapy AP in 86 patients, and both in 71 cases. AP was classified as Normal (< 100% upper limit), High (100% <= AP < 200%) or Very High (AP >= 200%). Osteosarcoma subtype was predominantly conventional. No correlation was found between subtype and chemotherapy response, local recurrence or survival. Pre-chemotherapy AP was raised more in the osteoblastic subtype. Post-chemotherapy AP and normalisation were the same among different subtypes. AP was not correlated with local recurrence. Normal or High pre-chemotherapy AP correlated with better survival at 10 years (64% and 70%) than Very High pre-chemotherapy AP (37%, P = 0.005). Post-chemotherapy AP correlated with survival (68%, 39% and 25% in the Normal, High and Very High group, P = 0.0007) and response to chemotherapy (P = 0.049). A pre-chemotherapy AP above twice Normal correlated with worse survival. If AP decreased after chemotherapy, but was still raised, survival was better, but still worse than if AP normalised. A raised post-chemotherapy AP predicts poor chemotherapy response. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2846 / 2852
页数:7
相关论文
共 27 条
[1]  
BACCI G, 1993, CANCER-AM CANCER SOC, V71, P1224, DOI 10.1002/1097-0142(19930215)71:4<1224::AID-CNCR2820710409>3.0.CO
[2]  
2-M
[3]   Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: Study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin [J].
Bacci, G ;
Ferrari, S ;
Delepine, N ;
Bertoni, F ;
Picci, P ;
Mercuri, M ;
Bacchini, P ;
del Prever, AB ;
Tienghi, A ;
Comandone, A ;
Campanacci, M .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) :658-663
[4]  
Bacci G, 2002, ONCOL REP, V9, P171
[5]   Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli Osteosarcoma-2 protocol: An updated report [J].
Bacci, G ;
Ferrari, S ;
Bertoni, F ;
Ruggieri, P ;
Picci, P ;
Longhi, A ;
Casadei, R ;
Fabbri, N ;
Forni, C ;
Versari, M ;
Campanacci, M .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (24) :4016-4027
[6]   Neoadjuvant therapy for localized extremity osteosarcoma.: Experience of the Cooperative Osteosarcoma Study Group COSS with 925 patients [J].
Bielack, S ;
Kempf-Bielack, B ;
Schwenzer, D ;
Birkfellner, T ;
Delling, G ;
Ewerbeck, V ;
Exner, GU ;
Fuchs, N ;
Göbel, U ;
Graf, N ;
Heise, U ;
Helmke, K ;
von Hochstetter, AR ;
Jürgens, H ;
Maas, R ;
Münchow, N ;
Salzer-Kuntschik, M ;
Treuner, J ;
Veltmann, U ;
Werner, M ;
Winkelmann, W ;
Zoubek, A ;
Kotz, R .
KLINISCHE PADIATRIE, 1999, 211 (04) :260-270
[7]   Prognostic factors in high-grade osteosarcoma of the extremities or trunk:: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols [J].
Bielack, SS ;
Kempf-Bielack, B ;
Delling, G ;
Exner, GU ;
Flege, S ;
Helmke, K ;
Kotz, R ;
Salzer-Kuntschik, M ;
Werner, M ;
Winkelmann, W ;
Zoubek, A ;
Jürgens, H ;
Winkler, K .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (03) :776-790
[8]   Colour Doppler ultrasound predicts chemotherapy response, but not survival in paediatric osteosarcoma [J].
Bramer, JAM ;
Gubler, FM ;
Maas, M ;
Bras, H ;
de Kraker, J ;
van der Eijken, JW ;
Schaap, GR .
PEDIATRIC RADIOLOGY, 2004, 34 (08) :614-619
[9]   Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: A European osteosarcoma intergroup study [J].
Bramwell, VHC ;
Steward, WP ;
Nooij, M ;
Whelan, J ;
Craft, AW ;
Grimer, RJ ;
Taminau, AHM ;
Cannon, SR ;
Malcolm, AJ ;
Hogendoorn, PCW ;
Uscinska, B ;
Kirkpatrick, AL ;
Machin, D ;
Van Glabbeke, MM .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) :3260-3269
[10]   PROGNOSTIC FACTORS IN OSTEOSARCOMA - A CRITICAL-REVIEW [J].
DAVIS, AM ;
BELL, RS ;
GOODWIN, PJ .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (02) :423-431